Viridian Therapeutics Inc (VRDN) — Cash Flow-to-Debt Ratio

Latest as of March 2026: -0.78x

Viridian Therapeutics Inc (VRDN) has a Cash Flow-to-Debt Ratio of -0.78x as of March 2026, meaning its operating cash flow of $-119.65 Million could theoretically repay -1% of its total liabilities ($153.01 Million) in one year. See Viridian Therapeutics Inc (VRDN) flexibility index to measure the company's free cash flow as a share of total liabilities.

CF-to-Debt Ratio

-0.78x
Operating CF / Total Liabilities

Operating Cash Flow

$-119.65 Million
USD

Total Liabilities

$153.01 Million
USD

Data as of

Mar 2026
Most recent filing

Viridian Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)

Historical debt coverage capacity for Viridian Therapeutics Inc across 14 annual periods. For the full cash flow conversion analysis, see Viridian Therapeutics Inc operating cash flow efficiency.

Annual Cash Flow-to-Debt Ratio for Viridian Therapeutics Inc (2012–2025)

Year-by-year debt coverage analysis for Viridian Therapeutics Inc.

Year CF-to-Debt Ratio Operating CF (USD) Total Liabilities YoY Change
2025 -1.56x $-276.39 Million $177.25 Million ▲ +52.5%
2024 -3.28x $-232.32 Million $70.76 Million ▲ +13.7%
2023 -3.81x $-184.17 Million $48.40 Million ▼ -62.3%
2022 -2.34x $-93.84 Million $40.03 Million ▲ +31.3%
2021 -3.41x $-54.58 Million $15.99 Million ▼ -28.6%
2020 -2.65x $-29.78 Million $11.22 Million ▼ -6.8%
2019 -2.49x $-36.06 Million $14.51 Million ▼ -37.0%
2018 -1.81x $-26.84 Million $14.80 Million ▲ +10.1%
2017 -2.02x $-28.17 Million $13.97 Million ▼ -27.8%
2016 -1.58x $-7.23 Million $4.58 Million ▲ +43.0%
2015 -2.77x $-6.90 Million $2.49 Million ▼ -162.4%
2014 -1.05x $-2.21 Million $2.10 Million ▼ -48.7%
2013 -0.71x $-1.17 Million $1.65 Million ▼ -176.1%
2012 -0.26x $-6.22 Million $24.22 Million
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.